Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov ID: NCT02771626

Public ClinicalTrials.gov record NCT02771626. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

Study identification

NCT ID: NCT02771626
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Calithera Biosciences, Inc; Industry
Enrollment: 118 participants

Conditions and interventions

Conditions

Interventions

CB-839 Drug
Nivolumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 1, 2016 (Actual)
Primary completion: Apr 24, 2020 (Actual)
Completion: Apr 24, 2020 (Actual)
Last update posted: Mar 17, 2023

2016 – 2020

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 13

Facility	City	State	ZIP	Site status
Honor Health	Scottsdale	Arizona	85016	—
Stanford University	Palo Alto	California	94304	—
University of Colorado	Aurora	Colorado	80045	—
University Cancer Blood Center	Athens	Georgia	30607	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02114	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
Karmanos Caner Center	Detroit	Michigan	48201	—
New York University	New York	New York	10016	—
Columbia University Medical Center	New York	New York	10032	—
Memorial Sloan Kettering Cancer Center	New York	New York	10655	—
University Hospitals Cleveland	Cleveland	Ohio	44106	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
Vanderbilt University	Nashville	Tennessee	37232	—
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—
Seattle Cancer Care Alliance/University of Washington	Seattle	Washington	98109	—
Northwest Medical Specialties	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02771626, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 17, 2023 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02771626 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →